Investigators from the Ontario Institute for Cancer Research and the University Health Network have synthesized triazolopyridopyrimidine and dihydroimidazopyridopyrimidine derivatives acting as eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer and peripheral neuropathy.
Researchers from the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and the Shanghai Institute of Organic Chemistry have divulged EGFR (L858R/T790M/C797S triple mutant) and EGFR (del19/T790M/C797S triple mutant) inhibitors reported to be useful for the treatment of cancer.
Shenzhen Zhongge Biotechnology Co. Ltd. prepared and tested cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of castration-resistant prostate cancer.
Bladder cancers (BCs) that invade the muscle layer are classified as muscle-invasive bladder cancers (MIBCs). The MIBC subtype accounts for around 25% of all BC cases, with a significant proportion of patients presenting distant metastases.
Metabolic reprogramming in cancer involves glycolytic enzymes acquiring noncanonical functions and acting as protein kinases, which contribute to tumor progression and present new therapeutic opportunities. While hexokinase domain-containing protein 1 (HKDC1), a hexokinase family member, has been implicated in tumor growth and immune evasion, its nonmetabolic roles remain poorly understood.
The three-dimensional analysis of cell types and their locations by spatial transcriptomics provides key information of their interactions within tissues or organs. Based on this technology, scientists at the Wellcome Sanger Institute have developed an AI tool called Nichecompass, which shows a comprehensive view of the cancer microenvironments, the different cells, their locations, and how they communicate with each other through different molecules inside the tumor. This AI could process data in an hour and compare samples before and after a treatment.
Astrazeneca plc is investing heavily in China, signing two R&D deals, worth up to about $8 billion in up-front payments and milestones combined, with Chinese companies Harbour Biomed Ltd. and Syneron Bio, establishing a joint venture with Shenzhen Kangtai Biological Products Co. (Biokangtai) for vaccines, and creating a new R&D center in Beijing through another $2.5 billion investment.
Roche Holding AG and the University of Liverpool in the U.K. launched an initiative to improve the early detection of rare eye cancers with the help of the Ventana DP 600 digital pathology slide scanner.
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified new benzazepinone derivatives acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer.
Work at Artivila (Shenzhen) Innovation Center Ltd. has led to the discovery of new leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of cancer, leprosy, tuberculosis, colitis, inflammatory bowel disease, Alzheimer’s, Parkinson’s and Huntington’s disease.
RSS
